Friday , March 29 2024
Home / SNB & CHF / Coronavirus: cheap drug substantially cuts severe case death risk, according to large UK trial

Coronavirus: cheap drug substantially cuts severe case death risk, according to large UK trial

Summary:
© Sudok1 | Dreamstime.com A trial at Oxford University suggests an existing low cost drug can cut the risk of death from Covid-19 substantially. Tests involving 6,000 hospitalised Covid-19 patients suggest the drug can cut the risk of death for those on ventilators from 40% to 28%. For patients needing oxygen the risk of death ...

Topics:
Investec considers the following as important: , , , , , , , , ,

This could be interesting, too:

Investec writes Some relief on Swiss electricity bills in pipeline

Investec writes Recent Swiss fire deaths prompt calls for fire detectors

Investec writes Swiss National Bank surprises with interest rate cut

Connor O'Keeffe writes Is the Violence in Haiti a Preview of a Libertarian Society?

Coronavirus: cheap drug substantially cuts severe case death risk, according to large UK trial

© Sudok1 | Dreamstime.com

A trial at Oxford University suggests an existing low cost drug can cut the risk of death from Covid-19 substantially.

Tests involving 6,000 hospitalised Covid-19 patients suggest the drug can cut the risk of death for those on ventilators from 40% to 28%. For patients needing oxygen the risk of death could be cut from 25% to 20%.

The findings are potentially the biggest breakthrough in Covid-19 treatment so far. Lead researcher Prof Martin Landray told the BBC that the findings suggested one life could be saved for every eight patients on a ventilator and one for every 20-25 treated with oxygen.

The drug, dexamethasone, is a steroid treatment that calms the immune response. A course of the globally available drug costs around £35.

However, the drug does not seem to help those with milder symptoms who do not need help breathing.


Tags: ,,,,,,,
About Investec
Investec
Investec is a distinctive Specialist Bank and Asset Manager. We provide a diverse range of financial products and services to our niche client base.

Leave a Reply

Your email address will not be published. Required fields are marked *